Jim Simons Regulus Therapeutics Inc. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Regulus Therapeutics Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 97,200 shares of RGLS stock, worth $158,436. This represents 0.0% of its overall portfolio holdings.

Number of Shares

97,200

Previous 118,100 17.7%

Holding current value

$158,436

Previous $211,000 27.96%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$1.46 - $1.9 $30,514 - $39,710	-20,900 Reduced 17.7%	97,200 $152,000
Q2 2024 Aug 09, 2024	BUY	$1.79 - $2.8 $76,254 - $119,279	42,600 Added 56.42%	118,100 $211,000
Q1 2024 May 13, 2024	BUY	$1.13 - $2.88 $23,616 - $60,192	20,900 Added 38.28%	75,500 $217,000
Q4 2023 Feb 13, 2024	BUY	$1.21 - $1.44 $5,445 - $6,480	4,500 Added 8.98%	54,600 $70,000
Q3 2023 Nov 14, 2023	BUY	$1.27 - $1.76 $5,080 - $7,040	4,000 Added 8.68%	50,100 $69,000
Q2 2023 Aug 11, 2023	BUY	$0.87 - $1.75 $6,351 - $12,775	7,300 Added 18.81%	46,100 $68,000
Q1 2023 May 12, 2023	BUY	$0.79 - $1.61 $3,160 - $6,440	4,000 Added 11.49%	38,800 $33,000
Q4 2022 Feb 13, 2023	BUY	$1.17 - $1.85 $2,808 - $4,440	2,400 Added 7.41%	34,800 $48,000
Q3 2022 Nov 14, 2022	BUY	$1.35 - $2.39 $5,805 - $10,277	4,300 Added 15.3%	32,400 $55,000
Q2 2022 Aug 12, 2022	BUY	$1.6 - $3.4 $44,960 - $95,540	28,100 New	28,100 $58,000

Others Institutions Holding RGLS

# of Institutions

Shares Held

56.5M

Call Options Held

79.3K

Put Options Held

20.3K

View Full List

About Regulus Therapeutics Inc.

Ticker RGLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,634,400
Market Cap $23.9M
Description
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-thre...

More about RGLS

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account